Alpha Teknova has launched its first proprietary product line, AAV-TekTM Solutions, created to address critical pain points in the AAV gene therapy development workflow.
The first product released in this line – the AAV-Tek AEX Buffer Screening Kit – is available for purchase today and can save gene therapy developers months of process development time.
The AAV-Tek AEX Buffer Screening Kit, developed by Teknova’s Research and Development team, is a proprietary, off-the-shelf selection of discrete buffers that significantly reduces the time it takes to find the ideal buffer formulation to optimise the separation of empty and full capsids during the anion exchange (AEX) purification step.
After conducting a robust design of experiments with hundreds of AEX runs, including extensive validation against four critical quality attributes (infectivity, recovery, purity, and peak separation), Teknova identified and verified a set of seven equilibration and elution buffers optimised for use across a variety of upstream workflows, transgenes, and downstream purification platforms.
We repeatedly hear from customers that separation of capsids is challenging and time consuming
“Launching our first proprietary product line, AAV-Tek Solutions, is a momentous milestone and a direct result of demonstrating our team's expertise in the end-to-end AAV gene therapy workflow,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “We repeatedly hear from customers that separation of capsids is challenging and time consuming, limiting the pace of innovation, and ultimately the delivery of life changing therapies to patients.
By addressing key bioprocessing bottlenecks with new, custom products, we can collaborate closely with our customers to help accelerate breakthroughs. Our first product, the AAV-Tek AEX Buffer Screening Kit, was created to optimise the purification process and is one-of-a-kind in the industry. I’m confident it will be a game-changer for gene therapy developers.”
By removing the need for repeated and extensive buffer formulation exploration, the AAV-Tek AEX Buffer Screening Kit can save gene therapy developers working with AAV2 months in their development timelines, enabling them to discover novel breakthroughs faster. Developers are able to seamlessly scale from process development to clinical production by leveraging Teknova’s industry-leading modular manufacturing platform, hands-on scientific and technical support teams, and more than 25 years of experience in reagents bioprocessing production.
The AAV-Tek AEX Buffer Screening Kit for AAV2 is available today for purchase via phone, email, or online, and is priced at $1,200. Additionally, Teknova will release a kit for AAV8 in the coming months and kits to address additional serotypes later this year.
